ClinicalTrials.gg
CompletedNCT00576316SMARTERUpdated Dec 16, 2010Results posted

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia

A Phase 4 interventional study of Symbicort Turbuhaler 160/4.5 in Asthma, sponsored by AstraZeneca. Completed at 1 site in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-16.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
201
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
120th of 248
201 · median 175
Started
2008
with 18 others
Phase 4
23 of 359
none open now
Registered
74th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 120th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2008, is one of 23 in phase 4, and was the 74th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the satisfaction level of patients using the Symbicort SMART approach for their asthma management.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma for past 6 months and treated with inhaled glucocorticosteroids for at least 3 months.
  • Patients who asthma is classified as uncontrolled or partially controlled as defined by GINA 2006 guidelines.

Exclusion criteria

Exclusion Criteria:

  • Patients already on Symbicort SMART treatment.
  • Patients who has respiratory tract infection 30 days before study enrolment.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
201 participants (actual)

Interventions

  • DrugSymbicort Turbuhaler 160/4.5
06

What researchers measure

Primary outcomes

  1. Change in Satisfaction With Asthma Treatment Questionnaire (SATQ) Scores From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART

    Difference/change in SATQ score between baseline and mean of 3 months and 6 months after SMART treatment as analysed by paired t-test. SATQ is a patient reported questionnaire which consists of 26 questions and scored to a scale of 1-7, the higher score indicating a greater level of satisfaction

    Time frame: 6 months after each patient was initially treated with Symbicort SMART

Secondary outcomes

  1. Changes in Asthma Control Questionnaire (ACQ-5) Score From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART

    Difference/change in ACQ-5 scores between baseline and mean of 3 months and 6 months after SMART treatment. ACQ-5 is a 5 question patient reported outcome measuring level of asthma control during the past 7 days and it is scored on scale of 0-6. 0 indicates no symptoms and 6 represents severe symptoms

    Time frame: 6 months after each patient was initially treated with Symbicort SMART

07

Results

Posted Dec 29, 2009

Participant flow

201 patients were recruited from 10 government hospital based outpatient clinics from Dec 2007 until May 2008

Participant flow — Overall Study
MilestoneSymbicort 160/4.5 Turbuhaler
Started201
Completed181
Not completed20
Withdrew: Adverse event9
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation9

Outcome measures

PrimaryChange in Satisfaction With Asthma Treatment Questionnaire (SATQ) Scores From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART

Difference/change in SATQ score between baseline and mean of 3 months and 6 months after SMART treatment as analysed by paired t-test. SATQ is a patient reported questionnaire which consists of 26 questions and scored to a scale of 1-7, the higher score indicating a greater level of satisfaction

Time frame:
6 months after each patient was initially treated with Symbicort SMART
Reported as:
Mean · Scores on a scale
Change in Satisfaction With Asthma Treatment Questionnaire (SATQ) Scores From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART
Scores on a scaleSymbicort 160/4.5 Turbuhaler
Change in Satisfaction With Asthma Treatment Questionnaire (SATQ) Scores From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART0.37 ± 0.73
SecondaryChanges in Asthma Control Questionnaire (ACQ-5) Score From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART

Difference/change in ACQ-5 scores between baseline and mean of 3 months and 6 months after SMART treatment. ACQ-5 is a 5 question patient reported outcome measuring level of asthma control during the past 7 days and it is scored on scale of 0-6. 0 indicates no symptoms and 6 represents severe symptoms

Time frame:
6 months after each patient was initially treated with Symbicort SMART
Reported as:
Mean · scores on a scale
Changes in Asthma Control Questionnaire (ACQ-5) Score From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART
scores on a scaleSymbicort 160/4.5 Turbuhaler
Changes in Asthma Control Questionnaire (ACQ-5) Score From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With SMART-0.97 ± 1.22

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort 160/4.5 Turbuhaler———
Most frequent serious events
Most frequent serious events
EventSymbicort 160/4.5 Turbuhaler
AsthmaRespiratory, thoracic and mediastinal disorders15/195
Upper Respiratory Tract InfectionInfections and infestations5/195
Secretion And PyrexiaGeneral disorders3/195
Congestive Cardiac FailureCardiac disorders1/195
Vestibular NeuronitisEar and labyrinth disorders1/195
Most frequent other events
Most frequent other events
EventSymbicort 160/4.5 Turbuhaler
Productive CoughRespiratory, thoracic and mediastinal disorders33/195
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders26/195
General discomfortGeneral disorders11/195

Baseline characteristics

Age Continuous
Age Continuous(years)Symbicort 160/4.5 Turbuhaler
Mean Age46.73 ± 12.31
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort 160/4.5 Turbuhaler
Female155
Male46
08

Study locations

1 site
  • Research Site
    Kuala Lumpur, Malaysia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2007
First posted
Dec 19, 2007
Start
Jan 2008
CompletionActual
Nov 2008
Results first posted
Dec 29, 2009
Last update
Dec 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00576316
Lead sponsor
AstraZeneca
First posted
Dec 19, 2007
Start date
Jan 2008
Completion
Nov 2008
Results posted
Dec 29, 2009
Last update
Dec 16, 2010

Study contacts

Akhmal Yusof, MD
study director · AstraZeneca
Aziah Ahmad Mahayiddin, MD
principal investigator · Kuala Lumpur Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion